The government initiatives for treatment of bipolar disorders, advancement in combination drugs, and growing demand for antidepressant drugs are expected to drive the growth of the market. Moreover, growing research and development activities conducted by government and nonprofit organizations are contributing to the growth of the market. For instance, Harvard University started Harvard brain science initiative (HBI) for R&D on bipolar disorders. This program has provided USD 3 million in funds to the research and development related to bipolar disorders. The side effects associated with therapy, low diagnosis rate, and dearth of experts may hamper the growth of the global market during the assessment period.
Bipolar Disorders Treatment Market Segment Insights
The global bipolar disorders and treatment market has been segmented on the basis of drug class, mechanism of action, and end user.
Bipolar Disorders Treatment Drug Type Insights
Based on drug type, the global market has been classified into mood stabilizer, antipsychotic drugs, antianxiety drugs, antidepressant drugs, anticonvulsants, and others.
Bipolar Disorders Treatment Mechanism of acion Insights
Based on the mechanism of action, the global market has been segmented into selective serotonin reuptake inhibitor, serotonin norepinephrine reuptake inhibitor, monoamine oxidase inhibitors, beta-blockers, tricyclic antidepressant drug, and others.
Bipolar Disorders Treatment End-User Insights
The global market, by end user, has been segmented into hospitals and clinics, multispecialty centers, and others.
Bipolar Disorders Treatmen Regional Insights
The bipolar disorders treatment market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The market in the Americas has further been segmented into North America and Latin America, with the North American market divided into the US and Canada. The European market has been bifurcated into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. The market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The bipolar disorders treatment market in the Middle East & Africa has been segmented into the Middle East and Africa.
Geographically, the market has been segmented into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The Americas are likely to dominate the global bipolar disorders and treatment market owing to technological advancement, presence of major players in the region, well-established healthcare system, and increasing cases of bipolar disorders in the region. According to the National Institute of Mental Health (NIMH), approximately 3% of adults in the US were suffering from bipolar disorders in 2016 and this percentage is expected to increase significantly in the future due to changing lifestyles.
| Report Attribute/Metric |
Details |
| Â Â Market Size |
  2032 :USD 5.8 Billion |
| Â Â CAGR |
  3.4% (2023–2032) |
| Â Â Base Year |
  2021 |
| Â Â Forecast Period |
  2023-2032 |
| Â Â Historical Data |
  2020 |
| Â Â Forecast Units |
  Value (USD Million) |
| Â Â Report Coverage |
  Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| Â Â Segments Covered |
  Drug Type, Mechanism of Action and End User |
| Â Â Geographies Covered |
  North America, Europe, Asia-Pacific, and Rest of the World (RoW) |
| Â Â Key Vendors |
  Allergan (Ireland), AstraZeneca (UK), Eli Lilly and Company(US), GlaxoSmithKline(UK), Abbott (US), Bristol-Myers Squibb (US), Johnson & Johnson (US), Pfizer Inc. (US), Cephalon Inc. (US), Otsuka America Pharmaceutical Inc. (US), and Gedeon Richter plc (Hungary) |
| Â Â Key Market Opportunities |
  side effects associated with therapy, low diagnosis rate, and dearth of experts |
| Â Â Key Market Drivers |
· government initiatives for treatment of bipolar disorders · advancement in combination drugs · growing demand for antidepressant drugs |
